Mustafa Bilal Ozbay, Serhat Degirmen, Aysenur Gullu, Bede Nnaemeka Nriagu, Yasin Ozen, Ozlem Ozcan Celebi, Cagri Yayla
{"title":"Comparative outcomes of Myval versus contemporary transcatheter heart valves: a systematic review and meta-analysis.","authors":"Mustafa Bilal Ozbay, Serhat Degirmen, Aysenur Gullu, Bede Nnaemeka Nriagu, Yasin Ozen, Ozlem Ozcan Celebi, Cagri Yayla","doi":"10.1007/s12928-025-01153-2","DOIUrl":null,"url":null,"abstract":"<p><p>Transcatheter aortic valve replacement is a key intervention for high-risk patients with severe aortic stenosis. Myval, a newer transcatheter heart valve (THV), shows promise, but a comprehensive comparison with other THVs is lacking. This study evaluates the safety and efficacy of Myval compared with contemporary THVs. A systematic review and meta-analysis of six studies involving 2335 patients was performed. Primary outcomes included all-cause mortality, cardiovascular mortality, new permanent pacemaker implantation (PPI), device success, early safety, acute kidney injury, stroke, vascular complications, and valve regurgitation. Myval was associated with significantly lower rates of new PPI (RR, 0.62; 95% CI 0.45-0.86; P = .004), higher rates of device success (RR, 1.08; 95% CI 1.01-1.16; P = .02), and early safety (RR, 1.15; 95% CI 1.05-1.27; P = .003) compared with contemporary THVs. No significant differences were observed in all-cause mortality, cardiovascular mortality, acute kidney injury, stroke, vascular complications, and valve regurgitation. Myval may offer better short-term outcomes in terms of new PPI, device success, and early safety compared with contemporary THVs. Larger, prospective studies with longer follow-ups are needed to confirm these findings.</p>","PeriodicalId":9439,"journal":{"name":"Cardiovascular Intervention and Therapeutics","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Intervention and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12928-025-01153-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Transcatheter aortic valve replacement is a key intervention for high-risk patients with severe aortic stenosis. Myval, a newer transcatheter heart valve (THV), shows promise, but a comprehensive comparison with other THVs is lacking. This study evaluates the safety and efficacy of Myval compared with contemporary THVs. A systematic review and meta-analysis of six studies involving 2335 patients was performed. Primary outcomes included all-cause mortality, cardiovascular mortality, new permanent pacemaker implantation (PPI), device success, early safety, acute kidney injury, stroke, vascular complications, and valve regurgitation. Myval was associated with significantly lower rates of new PPI (RR, 0.62; 95% CI 0.45-0.86; P = .004), higher rates of device success (RR, 1.08; 95% CI 1.01-1.16; P = .02), and early safety (RR, 1.15; 95% CI 1.05-1.27; P = .003) compared with contemporary THVs. No significant differences were observed in all-cause mortality, cardiovascular mortality, acute kidney injury, stroke, vascular complications, and valve regurgitation. Myval may offer better short-term outcomes in terms of new PPI, device success, and early safety compared with contemporary THVs. Larger, prospective studies with longer follow-ups are needed to confirm these findings.
期刊介绍:
Cardiovascular Intervention and Therapeutics (CVIT) is an international journal covering the field of cardiovascular disease and includes cardiac (coronary and noncoronary) and peripheral interventions and therapeutics. Articles are subject to peer review and complete editorial evaluation prior to any decision regarding acceptability. CVIT is an official journal of The Japanese Association of Cardiovascular Intervention and Therapeutics.